Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 11/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | RXRB | P28702 | 5/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21796840 | 1.00 | GRIN2B (0.43) | GRIN2BMAP4K4RXRBPIK3CDUSP30 | |
| SCHEMBL21796661 | 1.00 | GRIN2B (0.43) | GRIN2BMAP4K4RXRBPIK3CDUSP30 | |
| SCHEMBL20899405 | 0.86 | SCN9A (0.42) | MAP4K4PIK3CDUSP30 | |
| SCHEMBL20899406 | 0.86 | SCN9A (0.42) | MAP4K4PIK3CDUSP30 | |
| SCHEMBL22873464 | 0.86 | SCN9A (0.42) | MAP4K4PIK3CDUSP30 | |
| SCHEMBL28607925 | 0.85 | KMO (0.44) | MAP4K4PIK3CDUSP30 | |
| SCHEMBL21797145 | 0.85 | KMO (0.44) | MAP4K4PIK3CDUSP30 | |
| Formamide SCHEMBL28601016 | 0.80 | KMO (0.40) | MAP4K4PIK3CDUSP30 | |
| SCHEMBL21796691 | 0.80 | LRRK2 (0.52) | GRIN2BRXRBPIK3CD | |
| SCHEMBL21796693 | 0.80 | LRRK2 (0.52) | GRIN2BRXRBPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137510-B | Compound (I) | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| US-20200079777-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
| EP-3325449-A1 | COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017012576-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | LRRK2, PARK7, PINK1 | GRIN2B 274/4885MAP4K4 195/4885RXRB 4413/4885 |
| US-20200079777-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | GRIN2B 389/4885MAP4K4 289/4885RXRB 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.